TY - JOUR
T1 - HLA-DRB1 typing in rheumatoid arthritis
T2 - Predicting response to specific treatments
AU - O'Dell, James Robert
AU - Nepom, Barbara S.
AU - Haire, Claire
AU - Gersuk, Vivian H.
AU - Gaur, Lakshmi
AU - Moore, Gerald Francis
AU - Drymalski, Walter
AU - Palmer, William
AU - Eckhoff, P. James
AU - Klassen, Lynell Warren
AU - Wees, Steven
AU - Thiele, Geoffrey Milton
AU - Nepom, Gerald T.
PY - 1998
Y1 - 1998
N2 - Objective - To determine the predictive value of shared epitope alleles for response to treatment in patients with rheumatoid arthritis. Methods - Patients from our previously published triple DMARD study were tested for the presence of shared epitope alleles (DRB1 *0401,0404/0408, 0405,0101, 1001, and 1402). Patients who were shared epitope positive were then compared with those who were negative to see if there was a differential effect on therapeutic response. Results-Shared epitope positive patients were much more likely to achieve a 50% response if treated with methotrexate-sulphasalazine- hydroxychloroquine compared with methotrexate alone (94% responders versus 32%, p<0.0001). In contrast shared epitope negative patients did equally well regardless of treatment (88% responders for methotrexate-sulphasalazine- hydroxychloroquine versus 83% for methotrexate). Additionally, a trend toward an inverse relation of the gene dose was seen for response to methotrexate treatment (p=0.05). Conclusions - These data suggest that determining shared epitope status may provide clinical information useful in selecting among treatment options.
AB - Objective - To determine the predictive value of shared epitope alleles for response to treatment in patients with rheumatoid arthritis. Methods - Patients from our previously published triple DMARD study were tested for the presence of shared epitope alleles (DRB1 *0401,0404/0408, 0405,0101, 1001, and 1402). Patients who were shared epitope positive were then compared with those who were negative to see if there was a differential effect on therapeutic response. Results-Shared epitope positive patients were much more likely to achieve a 50% response if treated with methotrexate-sulphasalazine- hydroxychloroquine compared with methotrexate alone (94% responders versus 32%, p<0.0001). In contrast shared epitope negative patients did equally well regardless of treatment (88% responders for methotrexate-sulphasalazine- hydroxychloroquine versus 83% for methotrexate). Additionally, a trend toward an inverse relation of the gene dose was seen for response to methotrexate treatment (p=0.05). Conclusions - These data suggest that determining shared epitope status may provide clinical information useful in selecting among treatment options.
UR - http://www.scopus.com/inward/record.url?scp=14444268771&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=14444268771&partnerID=8YFLogxK
U2 - 10.1136/ard.57.4.209
DO - 10.1136/ard.57.4.209
M3 - Article
C2 - 9709176
AN - SCOPUS:14444268771
VL - 57
SP - 209
EP - 213
JO - Annals of the Rheumatic Diseases
JF - Annals of the Rheumatic Diseases
SN - 0003-4967
IS - 4
ER -